Recombinant Pan paniscus Homeobox protein MOX-1 (MEOX1)

How is MEOX1 genetically characterized in Pan paniscus?

MEOX1 in Pan paniscus has the following genetic characteristics:

The cDNA ORF clone sequences for MEOX1 have been retrieved from the NCBI Reference Sequence Database (RefSeq) .

How does Pan paniscus MEOX1 compare to orthologs in other species?

The MEOX1 gene is highly conserved across species, with orthologs identified in humans, zebrafish, and mice. In zebrafish, MEOX1 is studied in relation to Klippel-Feil syndrome, showing functional conservation. Human MEOX1 is implicated in Klippel-Feil syndrome 2, demonstrating disease-relevant conservation .

The study of MEOX1 across species provides insights into evolutionary conservation of developmental pathways. When designing cross-species experiments, researchers should account for species-specific variations in protein sequence, domain organization, and post-translational modifications .

What expression systems are optimal for producing recombinant Pan paniscus MEOX1?

Several expression systems have been validated for producing recombinant MEOX1:

For basic structural studies or antibody production, E. coli or yeast systems (like that used in ABIN1654589) may be sufficient . For functional studies investigating protein-protein interactions or signaling pathways, mammalian expression systems are recommended to ensure proper folding and post-translational modifications.

What purification strategies are most effective for recombinant MEOX1?

Effective purification of recombinant MEOX1 typically follows this methodological approach:

• Affinity chromatography: Using the fusion tag (His tag, GST tag, or Strep tag) as the primary capture step. For His-tagged MEOX1 (as in ABIN1654589), immobilized metal affinity chromatography (IMAC) with Ni-NTA resin is effective.

• Secondary purification: Ion exchange chromatography or size exclusion chromatography to remove co-purifying contaminants.

• Quality control: SDS-PAGE analysis to confirm >90% purity, Western blot to verify identity, and analytical SEC (HPLC) to assess homogeneity .

For sensitive applications such as protein-DNA binding studies or structural analysis, additional purification steps may be necessary to achieve >95% purity.

How can I validate the functional activity of recombinant MEOX1?

Validation of recombinant MEOX1 functional activity should include the following methodological approaches:

• DNA-binding assays: Electrophoretic mobility shift assay (EMSA) or chromatin immunoprecipitation (ChIP) to confirm binding to known target sequences.

• Reporter gene assays: Assessing transcriptional activation of known target genes, particularly p21 CIP1/WAF1 and p16 INK4a .

• Cell-based functional assays: Evaluating the protein's ability to induce cell cycle arrest in endothelial cells, which is a known function of MEOX1 .

• Protein-protein interaction studies: Co-immunoprecipitation or yeast two-hybrid assays to validate interactions with known binding partners.

The functional activity of MEOX1 can be significantly affected by the expression system used and the presence/absence of post-translational modifications, which should be considered when interpreting results.

How can MEOX1 be utilized in vascular research models?

MEOX1 plays a critical role in vascular development and disease, particularly in neointima formation. A methodological approach to studying MEOX1 in vascular research includes:

• Vascular injury models: Carotid artery injury using 2F-Forgaty can be used to study MEOX1's role in neointima formation. After vascular injury, MEOX1 expression increases time-dependently during neointima formation, with levels concurrently increasing in the adventitia, media, and neointima .

• Spatiotemporal analysis: MEOX1 shows distinctive expression patterns after vascular injury:

  • Day 1: Highly expressed in the adventitia compared to media

  • Day 14: Extensively expressed in media and neointima compared to adventitia

• Mechanistic studies: MEOX1 regulates Sca-1+ progenitor cell migration during neointima formation through the synergistic effect of Rho/CDC42 and SDF-1α/CXCR4 signaling pathways .

• Loss-of-function approaches: MEOX1 knockdown with shRNA can abolish Sca-1+ progenitor cell migration and neointima formation, providing a tool to study its functional significance .

Transwell invasion assays can be utilized to study MEOX1 and SDF-1α function in regulating Sca-1+ progenitor stem cell migration, using conditioned media from control or MEOX1-overexpressing cells .

What role does MEOX1 play in cell cycle regulation and how can this be studied?

MEOX1 regulates the cell cycle through direct transcriptional activation of cyclin-dependent kinase inhibitors. To study this function:

• Target gene expression analysis: MEOX1 activates p16 INK4a in a DNA binding-dependent manner, whereas it induces p21 CIP1/WAF1 in a DNA binding-independent manner .

• DNA-binding mutants: Create DNA-binding deficient MEOX1 mutants to differentiate between direct transcriptional activation and indirect regulatory mechanisms.

• Senescence assays: Measure cellular senescence markers following MEOX1 overexpression or knockdown, particularly in endothelial cells where MEOX1 has been implicated in dysfunction and atherosclerosis .

• Comparative analysis with MEOX2: MEOX1 and MEOX2 have been shown to be partially functionally redundant during development. Compare their abilities to activate p21 CIP1/WAF1 and p16 INK4a expression and induce endothelial cell cycle arrest .

How can Pan paniscus MEOX1 be used to investigate evolutionary aspects of developmental gene regulation?

Comparative studies of MEOX1 across species can reveal evolutionary conservation and divergence in developmental regulation:

• Cross-species sequence alignment: Compare MEOX1 sequences from Pan paniscus, humans, mice, and zebrafish to identify conserved and divergent domains.

• Functional complementation studies: Express Pan paniscus MEOX1 in zebrafish meox1 mutants (tm26/tm26) to determine if it can rescue the Klippel-Feil syndrome phenotype .

• ChIP-seq comparative analysis: Compare genome-wide binding profiles of MEOX1 from different species to identify conserved and species-specific target genes.

• Developmental expression comparison: Use in situ hybridization to compare spatiotemporal expression patterns of MEOX1 during embryonic development across species.

This approach can provide insights into the evolutionary conservation of MEOX1's role in developmental processes and disease pathogenesis.

How is MEOX1 implicated in Klippel-Feil syndrome and how can recombinant protein be used to study this?

MEOX1 is implicated in Klippel-Feil syndrome 2 (KFS2), a congenital disorder characterized by fusion of cervical vertebrae. Research approaches using recombinant MEOX1 include:

Methodological approaches include:

• Functional domain mapping: Using truncated or mutated recombinant MEOX1 proteins to identify domains critical for normal development and implicated in KFS2.

• Rescue experiments: Introducing wild-type recombinant MEOX1 into zebrafish meox1 mutants to assess phenotypic rescue.

• Protein-protein interaction studies: Identifying interacting partners of MEOX1 that may be disrupted in KFS2 using co-immunoprecipitation with recombinant MEOX1.

• ChIP-seq analysis: Identifying genomic binding sites of recombinant MEOX1 to understand its regulatory network in normal development and how this is perturbed in KFS2 .

What role does MEOX1 play in fibrosis and how can this be investigated experimentally?

MEOX1 has been identified as a potential cell-specific, druggable target in cardiac fibrosis and is also implicated in fibrosis of other organs:

• Expression analysis: MEOX1 expression is increased in human heart, lung, liver, and kidney fibroblasts after TGFβ stimulation, suggesting a role in fibrotic responses .

• Single-cell genomic analysis: Recent studies using single-cell genomic technology have identified MEOX1 as a potential cell-specific, druggable target in cardiac fibrosis .

• Functional studies: Investigating the effect of MEOX1 inhibition on fibroblast activation, proliferation, and extracellular matrix production in response to pro-fibrotic stimuli.

• Animal models: Developing and characterizing MEOX1 knockout or conditional knockout animals to study its role in fibrosis in vivo.

This research direction is particularly relevant given the limited therapeutic options for fibrosis and the potential of MEOX1 as a novel druggable target.

What are common challenges in expressing and purifying functional Pan paniscus MEOX1?

Researchers frequently encounter several challenges when working with recombinant MEOX1:

• Solubility issues: MEOX1 contains a homeodomain that can aggregate when overexpressed. Optimization strategies include:

  • Lowering expression temperature (16-18°C)

  • Using solubility-enhancing fusion tags (MBP, SUMO)

  • Adding low concentrations of non-ionic detergents during purification

• DNA contamination: As a DNA-binding protein, MEOX1 often co-purifies with bacterial or host cell DNA. This can be addressed by:

  • Including DNase treatment during lysis

  • Incorporating high-salt washes (500mM-1M NaCl) during affinity purification

  • Using heparin chromatography as a secondary purification step

• Post-translational modifications: Depending on the research question, ensuring proper post-translational modifications may be critical. Consider:

  • Using mammalian expression systems for studies requiring authentic modifications

  • Implementing phosphatase inhibitors during purification if studying phosphorylation states

  • Verification of modification status by mass spectrometry

• Functional validation: Confirming that the recombinant protein retains physiological activity through DNA-binding assays or reporter gene activation .

How can I design experiments to distinguish between MEOX1 and MEOX2 functions?

MEOX1 and MEOX2 show partial functional redundancy, creating challenges in distinguishing their specific roles:

• Domain-specific antibodies: Develop antibodies targeting non-conserved regions to specifically detect each protein in Western blots, immunohistochemistry, or ChIP experiments.

• Paralog-specific knockdown: Design siRNAs or shRNAs targeting unique regions of each mRNA to achieve selective knockdown.

• Rescue experiments: In knockdown or knockout models, introduce expression constructs for either MEOX1 or MEOX2 to determine if each can compensate for the other's loss.

• Domain swapping: Create chimeric proteins by swapping domains between MEOX1 and MEOX2 to identify regions responsible for unique functions.

• Comparative ChIP-seq: Perform parallel ChIP-seq experiments for MEOX1 and MEOX2 to identify common and distinct genomic binding sites.

Studies have shown that both MEOX1 and MEOX2 can activate p21 CIP1/WAF1 and p16 INK4a, but they may do so through different mechanisms: MEOX1 and MEOX2 activate p16 INK4a in a DNA binding-dependent manner, whereas they induce p21 CIP1/WAF1 in a DNA binding-independent manner .

What considerations are important when designing MEOX1 overexpression or knockdown experiments?

When manipulating MEOX1 expression levels, consider these methodological approaches:

• Vector selection for overexpression:

  • Use inducible systems (Tet-On/Off) to control expression timing and level

  • Include appropriate tags for detection (Flag, HA) but verify they don't interfere with function

  • Consider tissue-specific promoters for in vivo studies

• Knockdown strategy optimization:

  • Test multiple siRNA/shRNA sequences targeting different regions

  • Include rescue controls with shRNA-resistant MEOX1 constructs

  • For the neointima formation model, adenoviral delivery of shMeox1 has been validated

• Phenotypic analysis timeline:

  • For vascular studies, collect tissue at multiple timepoints (1, 3, 7, and 14 days) to capture dynamic changes in MEOX1 expression and function

  • For cell cycle studies, analyze both early (p21 induction) and late (p16 activation) effects

• Functional readouts:

  • For vascular studies: measure Sca-1+ cell migration using Transwell invasion assays

  • For cell cycle regulation: assess proliferation rates, senescence markers, and target gene expression

  • For developmental studies: analyze tissue-specific differentiation markers

These considerations ensure robust experimental design and valid interpretation of MEOX1 function in various biological contexts.